These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 26732628)

  • 41. Intensive chemotherapy for childhood acute lymphoblastic leukemia: results of the randomized intercontinental trial ALL IC-BFM 2002.
    Stary J; Zimmermann M; Campbell M; Castillo L; Dibar E; Donska S; Gonzalez A; Izraeli S; Janic D; Jazbec J; Konja J; Kaiserova E; Kowalczyk J; Kovacs G; Li CK; Magyarosy E; Popa A; Stark B; Jabali Y; Trka J; Hrusak O; Riehm H; Masera G; Schrappe M
    J Clin Oncol; 2014 Jan; 32(3):174-84. PubMed ID: 24344215
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prognostic relevance of TLX3 (HOX11L2) expression in childhood T-cell acute lymphoblastic leukaemia treated with Berlin-Frankfurt-Münster (BFM) protocols containing early and late re-intensification elements.
    Attarbaschi A; Pisecker M; Inthal A; Mann G; Janousek D; Dworzak M; Pötschger U; Ullmann R; Schrappe M; Gadner H; Haas OA; Panzer-Grümayer R; Strehl S;
    Br J Haematol; 2010 Jan; 148(2):293-300. PubMed ID: 19821827
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Deletion of 11q23 is a highly specific nonrandom secondary genetic abnormality of ETV6/RUNX1-rearranged childhood acute lymphoblastic leukemia.
    Attarbaschi A; Mann G; Strehl S; König M; Steiner M; Jeitler V; Lion T; Dworzak MN; Gadner H; Haas OA
    Leukemia; 2007 Mar; 21(3):584-6. PubMed ID: 17215856
    [No Abstract]   [Full Text] [Related]  

  • 44. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
    Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
    J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Atopic disease and childhood acute lymphoblastic leukemia.
    Schüz J; Morgan G; Böhler E; Kaatsch P; Michaelis J
    Int J Cancer; 2003 Jun; 105(2):255-60. PubMed ID: 12673688
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Genetic predisposition to acute lymphoblastic leukemia: Overview on behalf of the I-BFM ALL Host Genetic Variation Working Group.
    Kratz CP; Stanulla M; Cavé H
    Eur J Med Genet; 2016 Mar; 59(3):111-5. PubMed ID: 26699264
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MTHFR 677 (C-->T) polymorphism is not relevant for prognosis or therapy-associated toxicity in pediatric NHL: results from 484 patients of multicenter trial NHL-BFM 95.
    Seidemann K; Book M; Zimmermann M; Meyer U; Welte K; Stanulla M; Reiter A
    Ann Hematol; 2006 May; 85(5):291-300. PubMed ID: 16463153
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Incidence and outcome of TCF3-PBX1-positive acute lymphoblastic leukemia in Austrian children.
    Kager L; Lion T; Attarbaschi A; Koenig M; Strehl S; Haas OA; Dworzak MN; Schrappe M; Gadner H; Mann G;
    Haematologica; 2007 Nov; 92(11):1561-4. PubMed ID: 18024406
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Recent advances in genetic predisposition to pediatric acute lymphoblastic leukemia.
    Bloom M; Maciaszek JL; Clark ME; Pui CH; Nichols KE
    Expert Rev Hematol; 2020 Jan; 13(1):55-70. PubMed ID: 31657974
    [No Abstract]   [Full Text] [Related]  

  • 50. Treatment outcome of CRLF2-rearranged childhood acute lymphoblastic leukaemia: a comparative analysis of the AIEOP-BFM and UK NCRI-CCLG study groups.
    Attarbaschi A; Morak M; Cario G; Cazzaniga G; Ensor HM; te Kronnie T; Bradtke J; Mann G; Vendramini E; Palmi C; Schwab C; Russell LJ; Schrappe M; Conter V; Mitchell CD; Strehl S; Zimmermann M; Pötschger U; Harrison CJ; Stanulla M; Panzer-Grümayer R; Haas OA; Moorman AV;
    Br J Haematol; 2012 Sep; 158(6):772-7. PubMed ID: 22816614
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Age distribution of childhood acute lymphoblastic leukemia cases suggests etiological clues.
    Cocco P; Rapallo M; Biddau P; Murgia G; Targhetta R
    Leukemia; 1996 Sep; 10(9):1558-9. PubMed ID: 8751481
    [No Abstract]   [Full Text] [Related]  

  • 52. Immunodeficiency and Hodgkin's disease: treatment and outcome in the DAL HD78-90 and GPOH HD95 studies.
    Niehues T; Schellong G; Dörffel W; Bucsky P; Mann G; Körholz D; Göbel U
    Klin Padiatr; 2003; 215(6):315-20. PubMed ID: 14677095
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Germline genetic variation in ETV6 and risk of childhood acute lymphoblastic leukaemia: a systematic genetic study.
    Moriyama T; Metzger ML; Wu G; Nishii R; Qian M; Devidas M; Yang W; Cheng C; Cao X; Quinn E; Raimondi S; Gastier-Foster JM; Raetz E; Larsen E; Martin PL; Bowman WP; Winick N; Komada Y; Wang S; Edmonson M; Xu H; Mardis E; Fulton R; Pui CH; Mullighan C; Evans WE; Zhang J; Hunger SP; Relling MV; Nichols KE; Loh ML; Yang JJ
    Lancet Oncol; 2015 Dec; 16(16):1659-66. PubMed ID: 26522332
    [TBL] [Abstract][Full Text] [Related]  

  • 54. BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: results of DCLSG protocol ALL-8 (1991-1996).
    Kamps WA; Bökkerink JP; Hakvoort-Cammel FG; Veerman AJ; Weening RS; van Wering ER; van Weerden JF; Hermans J; Slater R; van den Berg E; Kroes WG; van der Does-van den Berg A
    Leukemia; 2002 Jun; 16(6):1099-111. PubMed ID: 12040440
    [TBL] [Abstract][Full Text] [Related]  

  • 55. No evidence of a trial effect in newly diagnosed pediatric acute lymphoblastic leukemia.
    Koschmann C; Thomson B; Hawkins DS
    Arch Pediatr Adolesc Med; 2010 Mar; 164(3):214-7. PubMed ID: 20194252
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intensive BFM chemotherapy for childhood ALL: interim analysis of the AIEOP-ALL 91 study. Associazione Italiana Ematologia Oncologia Pediatrica.
    Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi A; Miniero R; Di Tullio MT; Lo Nigro L; Pession A; Rondelli R; Messina C; Santoro N; Mori PG; De Rossi G; Tamaro P; Silvestri D; Biondi A; Basso G; Masera G
    Haematologica; 1998 Sep; 83(9):791-9. PubMed ID: 9825576
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Perinatal and familial risk factors for acute lymphoblastic leukemia in a Swedish national cohort.
    Crump C; Sundquist J; Sieh W; Winkleby MA; Sundquist K
    Cancer; 2015 Apr; 121(7):1040-7. PubMed ID: 25417823
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Stem-cell transplantation in children with acute lymphoblastic leukemia: A prospective international multicenter trial comparing sibling donors with matched unrelated donors-The ALL-SCT-BFM-2003 trial.
    Peters C; Schrappe M; von Stackelberg A; Schrauder A; Bader P; Ebell W; Lang P; Sykora KW; Schrum J; Kremens B; Ehlert K; Albert MH; Meisel R; Matthes-Martin S; Gungor T; Holter W; Strahm B; Gruhn B; Schulz A; Woessmann W; Poetschger U; Zimmermann M; Klingebiel T
    J Clin Oncol; 2015 Apr; 33(11):1265-74. PubMed ID: 25753432
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Malignant diseases in Noonan syndrome and related disorders.
    Hasle H
    Horm Res; 2009 Dec; 72 Suppl 2():8-14. PubMed ID: 20029231
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatment reduction in highly selected standard-risk childhood acute lymphoblastic leukemia. The AIEOP ALL-9501 study.
    Aricò M; Conter V; Valsecchi MG; Rizzari C; Boccalatte MF; Barisone E; Messina C; De Rossi G; Lo Nigro L; Pession A; Locatelli F; Micalizzi C; Basso G
    Haematologica; 2005 Sep; 90(9):1186-91. PubMed ID: 16154841
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.